BeOne Medicines (ONC) Operating Leases: 2019-2025
Historic Operating Leases for BeOne Medicines (ONC) over the last 7 years, with Sep 2025 value amounting to $51.4 million.
- BeOne Medicines' Operating Leases rose 58.34% to $51.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.4 million, marking a year-over-year increase of 58.34%. This contributed to the annual value of $44.3 million for FY2024, which is 0.17% up from last year.
- Latest data reveals that BeOne Medicines reported Operating Leases of $51.4 million as of Q3 2025, which was down 4.73% from $53.9 million recorded in Q2 2025.
- BeOne Medicines' 5-year Operating Leases high stood at $65.0 million for Q4 2021, and its period low was $17.7 million during Q1 2024.
- In the last 3 years, BeOne Medicines' Operating Leases had a median value of $35.4 million in 2024 and averaged $38.0 million.
- As far as peak fluctuations go, BeOne Medicines' Operating Leases plummeted by 45.54% in 2024, and later soared by 209.76% in 2025.
- BeOne Medicines' Operating Leases (Quarterly) stood at $65.0 million in 2021, then dropped by 9.86% to $58.6 million in 2022, then fell by 24.52% to $44.2 million in 2023, then grew by 0.17% to $44.3 million in 2024, then skyrocketed by 58.34% to $51.4 million in 2025.
- Its Operating Leases was $51.4 million in Q3 2025, compared to $53.9 million in Q2 2025 and $54.9 million in Q1 2025.